BMY - Exelixis started at buy at Wainwright on targeted oncology pipeline
2023-09-26 11:47:19 ET
More on Exelixis
- Exelixis: Predominantly Single Molecule Cancer Franchise (Rating Downgrade)
- Exelixis: Positive Advanced Pancreatic/Extra-Pancreatic Neuroendocrine Tumor Data Brings 2 Big Catalysts On Deck
- Exelixis: Long-Term Problem Isn't Shareholder Activism - It's Cabo Patent Expiry
- Exelixis inks licensing deal with Insilico for tumor candidate
- Exelixis reports positive results for Cabometyx in pancreatic cancer type
For further details see:
Exelixis started at buy at Wainwright on targeted oncology pipeline